A Brazilian court has stripped the patent protection of a company selling hepatitis C treatment in the country. A presidential candidate pushed for the move against Gilead Sciences Inc to pave the way for cheaper generics.

The ruling invalidates the exclusivity patent for the drug sofosbuvir – sold as Sovaldi. The request was filed early September by presidential candidate Marina Silva and her running mate, with them stating such a move would significantly reduce costs for patients.

Gilead came under criticism for prices of $1,000 a pill in the US. India, along with other nations and consumer groups have also challenged patents on the drug.

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!